ClinicalTrials.gg
RecruitingNCT07947043Updated Nov 18, 2026

Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection

A Phase 1 interventional study of Autologous Tumor-Infiltrating Lymphocyte Injection in Recurrent or Metastatic Lung Cancer or Cervical Cancer, sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionLung NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lung Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tongji Hospital · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2025, registered Jan 2026).
  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 847 studies in Lung Neoplasms with a site in China — 374 open to participants now, 421 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
538th of 588
18 · median 90
Started
2025
with 107 others
Phase 1
75 of 847
44 open now
Primary completion
2027-12
later than 302 of 420 live
Registered
751st of 847
by date

Among the 847 studies in Lung Neoplasms with a site in China, this one is the 538th largest by planned enrollment of the 588 interventional ones that give a count, is one of 108 that started in 2025, is one of 75 in phase 1, reaches primary completion later than 302 of the 420 other live ones, and was the 751st registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

374 of the 847 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

369 more — sign in →

All 374 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 847 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a single - center, single - arm, open - label, single - dose, dose - escalation exploratory study. The main purpose is to evaluate the safety and tolerability of autologous tumor - infiltrating lymphocyte injection in the treatment of recurrent or metastatic lung cancer or cervical cancer. Meanwhile, it will also preliminarily explore the effectiveness, PK characteristics, PD characteristics and changes in immune - related parameters of autologous tumor - infiltrating lymphocyte injection in subjects with recurrent or metastatic lung cancer or cervical cancer.

03

Conditions studied

  • Recurrent or Metastatic Lung Cancer or Cervical Cancer

Browse trials for

04

In context

Lung Neoplasms Reclassified

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

This study's planned enrollment of 18 is below the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Tongji Hospital is the lead sponsor of 390 studies on the registry; 211 are open to participants now.

Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.The patient voluntarily signs the form and is able to complete the study procedures, follow-up examinations and treatments.
  • 2.Aged 18 to 75 years old, regardless of gender.
  • 3. (ECOG) performance status score of 0-1.
  • 4.Patients with confirmed recurrent or malignant lung cancer or cervical cancer (confirmed by cytology or histopathology) who have failed or are intolerant to standard treatment, or have no standard treatment plan.
  • 5.The subject has at least one eligible tumor lesion/tissue for TIL preparation.
  • 6.After TIL sampling and excisional , the subject must have at least one measurable tumor lesion in accordance with the 1.1 criteria.
  • 7.Expected survival time > 6 months.
  • 8.Sufficient hematological and end-organ function as defined by the following laboratory test results, which must be completed within 7 days before TIL tumor tissue collection: Routine blood test: White blood cell count ≥ 2.5×10⁹/L; (ANC) ≥ 1.5×10⁹/L; Absolute lymphocyte count (ALC) ≥ 0.7×10⁹/L; (PLT) ≥ 100×10⁹/L; (HGB) ≥ 90g/L; Coagulation function: (INR) ≤ 1.5×, unless anticoagulant therapy was received within the previous 7 days; Activated partial thromboplastin time (APTT) ≤ 1.5×ULN, unless anticoagulant therapy was received within the previous 7 days; Renal function: Serum creatinine ≤ 1.5mg/dL (or 132.6μmol/L) or ≥ 60mL/min; Urine protein \< 2+ in routine urine test, or 24-hour urine protein quantification \< 1g; Liver function: (AST/SGOT) ≤ 3×ULN; Alanine aminotransferase (ALT/SGPT) ≤ 3×ULN; Total (TBIL) ≤ 1.5×ULN. Note: For patients with liver metastasis or primary liver tumor lesions, AST and ALT must be ≤ 5×ULN; For patients with a history of Gilbert's syndrome or suspected of having the disease, TBIL must be ≤ 3×ULN.
  • 9.Toxic reactions caused by previous treatment (excluding disease-related ones) have recovered to ≤ Grade 1 before enrollment (excluding alopecia and ≤ Grade 2 neurotoxicity caused by chemotherapy drugs).
  • 10.Women of childbearing age must have a negative serum pregnancy test within 7 days before enrollment. Any male or female patient of must agree to use effective methods from enrollment until at least 6 months after TIL cell infusion. A patient is considered to have childbearing potential as judged by the investigator if he/she is biologically capable of having children and has normal sexual activity. Female patients without childbearing potential must meet at least one of the following criteria: Has undergone hysterectomy or bilateral oophorectomy; Medically confirmed ovarian failure; Medically confirmed (at least 12 consecutive months of amenorrhea).
  • 11.Able to comply with the study protocol as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • 1.Patients with only bone lesions or central nervous system metastatic lesions.
  • 2.Patients who have previously received any adoptive cell therapy.
  • 3.Patients who have received any systemic anti-tumor treatment (including chemotherapy, radiotherapy, molecular targeted therapy, etc.) within 4 weeks before preconditioning.
  • 4.Patients who have received systemic therapy for (≥10mg/day, excluding inhaled therapy, local therapy or physiological replacement therapy) or other immunosuppressive drug therapy within 2 weeks before preconditioning.
  • 5.Patients who have undergone major surgery deemed unsuitable for enrollment by the investigator within 4 weeks before screening, or plan to undergo other major surgeries (excluding the planned surgery for TIL cell preparation as specified in the protocol) during the study period.
  • 6.Patients with other malignant tumors within 5 years before screening or at the same time (excluding patients with locally treated malignant tumors who do not require treatment for more than 1 year and have no significant recurrence risk as judged by the investigator).
  • 7.Patients with active or suspected or inflammatory diseases (including but not limited to rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, autoimmune hemolytic anemia, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis, ulcerative colitis, Crohn's disease, etc.).
  • 8.Patients with a history of organ transplantation or hematopoietic stem cell transplantation.
  • 9.Patients with any of the following infections: (positive for hepatitis B surface antigen [HbsAg] and/or hepatitis B core antibody [HbcAb]; patients with HBVDNA \< 1000 copies/ml are eligible for enrollment); (positive for HCV antibody test and positive for HCV-RNA test); Patients with systemic active infections requiring antibiotic treatment (e.g., sepsis, acteremia, fungemia, etc.); Patients with congenital or acquired immunodeficiency (including but not limited to severe combined immunodeficiency disease, patients with infection, etc.); Patients positive for TP antibody or HTLV-1 antibody.
  • 10.Patients who have received or attenuated vaccines within 4 weeks before preconditioning.
  • 11.Patients with symptomatic and/or untreated (patients whose symptoms are stable for ≥14 days after clear treatment before preconditioning may be considered for enrollment).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Autologous Tumor-Infiltrating Lymphocyte Injection

    Autologous Tumor-Infiltrating Lymphocyte Injection with a single administration dose of 1×10¹⁰ (±20%), 3×10¹⁰ (±20%), and 5×10¹⁰ (±20%) cells per person per administration respectively.

    Biological: Autologous Tumor-Infiltrating Lymphocyte Injection

Interventions

  • BiologicalAutologous Tumor-Infiltrating Lymphocyte Injection

    DK008

07

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate (ORR) is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) to treatment, as assessed by imaging or clinical criteria. Tumor response is typically evaluated using standardized criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 12 months after first dose

Secondary outcomes

  1. PFS

    Progression-Free Survival (PFS) is defined as the time from the date of randomization (or initiation of treatment) to the date of disease progression or death from any cause, whichever occurs first. Disease progression is assessed according to standardized criteria such as RECIST version 1.1

    Time frame: From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.

  2. DOR

    Duration of Response (DOR) is defined as the time from the first documented evidence of a complete response (CR) or partial response (PR) until the date of disease progression or death from any cause, whichever occurs first. Tumor responses are assessed based on standardized criteria such as RECIST version 1.1.

    Time frame: From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.

  3. OS

    Overall Survival (OS) is defined as the time from the date of randomization (or initiation of treatment) to the date of death from any cause.

    Time frame: From date of first study treatment until the date of death from any cause, whichever comes first, assessed up to 60 months.

Other outcomes

  1. T Cell Subsets Associated with Pharmacokinetics

    Pharmacokinetic (PK) assessments were conducted to evaluate the absorption, distribution, metabolism, and excretion of the study drug. Immunophenotyping of T cell subsets associated with study drug pharmacokinetics. Measurements include absolute cell counts, relative percentages, and percentage change from baselin.

    Time frame: Within 30min before TIL infusion in day0, and Day1±1 hours, Day2±2 hours, Day4±1 day, Day7±1 day, Day14±1 day,Day21±1 day, Day28±1 day, Day42±3 days post TIL infusion

  2. PD-Related T Cell Subsets

    Pharmacodynamic (PD) assessments were performed to evaluate the biological effects and mechanism of action of the study drug. Immunophenotyping of efficacy-associated T cell subsets by flow cytometry.

    Time frame: Within 30 minutes prior to TIL infusionin Day0, Day14±1 day, Day28±1 day, Day42±3 days,Day84±3 days, Day126±3 days, Day168±3 days after TIL infusion, and at early withdrawal visit.

  3. ADA

    Anti-drug antibody (ADA) assessments were performed to evaluate the immunogenicity of the study drug.

    Time frame: Within 30 minutes prior to TIL infusion in Day0, at Day7±1 day, Day14±1 day, Day28±1 day, and Day42±3 day after TIL infusion.

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 163 non-industry phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 90. This study's planned 32 months is below that.

Counting every sponsor, half of 292 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Nov 18, 2026
StartActual
Apr 22, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947043
Lead sponsor
Tongji Hospital
Collaborators
Jiangsu Dekang Biotechnology Co., Ltd
Responsible party
Qian Chu (Chief Physician, Tongji Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Apr 22, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion